Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | TPO | P07202 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11998329 | 0.81 | TRPV1 (0.46) | TRPV1HTR2ASLC6A4KCNH2DAO | |
| SCHEMBL11997974 | 0.78 | TRPV1 (0.49) | TRPV1HTR2ASLC6A4KCNH2IDO1 | |
| SCHEMBL11910682 | 0.77 | TRPV1 (0.44) | TRPV1DAOIDO1PDE3BPDE3A | |
| SCHEMBL3094588 | 0.76 | TRPV1 (0.41) | TRPV1DAOIDO1PDE3BPDE3A | |
| SCHEMBL3096219 | 0.76 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL11910661 | 0.74 | TRPV1 (0.41) | TRPV1HTR2ASLC6A4DAOIDO1 | |
| SCHEMBL18874188 | 0.72 | IDO1 (0.51) | TRPV1SLC6A4DAOIDO1 | |
| SCHEMBL25530531 | 0.65 | PDE3B (0.45) | TRPV1DAOIDO1PDE3BPDE3A | |
| SCHEMBL25977970 | 0.65 | PPARG (0.43) | HTR2ASLC6A4KCNH2DAOIDO1 | |
| Ammonia Solution, Strong SCHEMBL4339853 | 0.63 | PPARG (0.42) | HTR2ASLC6A4KCNH2DAOIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009117626-A2 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-09-24 | — | — | WO | disclosed |